Teva puts GSK and Amarin on notice with generic Lovaza launch

Lovaza--Courtesy of GlaxoSmithKline

Watch out, GlaxoSmithKline--and Amarin. Teva Pharmaceutical Industries ($TEVA) has launched its generic version of Glaxo's ($GSK) fish-oil pill, Lovaza, designed to lower triglyceride levels in patients with cardiovascular disease. Lovaza delivers $1.1 billion in U.S. sales for Glaxo annually, Teva says. But GSK isn't the only company likely to suffer from Teva's generic. Amarin's ($AMRN) rival product Vascepa will have to face the competition, too. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.